Unveiling Pharmacogenomics Insights into Circular RNAs: Toward Precision Medicine in Cancer Therapy DOI Creative Commons
Saud Alqahtani, Taha Alqahtani, Krishnaraju Venkatesan

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 535 - 535

Published: April 5, 2025

Pharmacogenomics is revolutionizing precision medicine by enabling tailored therapeutic strategies based on an individual genetic and molecular profile. Circular RNAs (circRNAs), a distinct subclass of endogenous non-coding RNAs, have recently emerged as key regulators drug resistance, tumor progression, responses. Their covalently closed circular structure provides exceptional stability resistance to exonuclease degradation, positioning them reliable biomarkers novel targets in cancer management. This review comprehensive analysis the interplay between circRNAs pharmacogenomics, focusing their role modulating metabolism, efficacy, toxicity profiles. We examine how circRNA-mediated regulatory networks influence chemotherapy alter targeted therapy responses, impact immunotherapy outcomes. Additionally, we discuss emerging experimental tools bioinformatics techniques for studying circRNAs, including multi-omics integration, machine learning-driven biomarker discovery, high-throughput sequencing technologies. Beyond diagnostic potential, are being actively explored agents delivery vehicles. Recent advancements circRNA-based vaccines, engineered CAR-T cells, synthetic circRNA therapeutics highlight transformative potential oncology. Furthermore, address challenges standardization, reproducibility, clinical translation, emphasizing need rigorous validation frameworks facilitate integration into practice. By incorporating profiling pharmacogenomic strategies, this underscores paradigm shift toward highly personalized therapies. hold immense overcome enhance treatment optimize patient outcomes, marking significant advancement

Language: Английский

Unveiling Pharmacogenomics Insights into Circular RNAs: Toward Precision Medicine in Cancer Therapy DOI Creative Commons
Saud Alqahtani, Taha Alqahtani, Krishnaraju Venkatesan

et al.

Biomolecules, Journal Year: 2025, Volume and Issue: 15(4), P. 535 - 535

Published: April 5, 2025

Pharmacogenomics is revolutionizing precision medicine by enabling tailored therapeutic strategies based on an individual genetic and molecular profile. Circular RNAs (circRNAs), a distinct subclass of endogenous non-coding RNAs, have recently emerged as key regulators drug resistance, tumor progression, responses. Their covalently closed circular structure provides exceptional stability resistance to exonuclease degradation, positioning them reliable biomarkers novel targets in cancer management. This review comprehensive analysis the interplay between circRNAs pharmacogenomics, focusing their role modulating metabolism, efficacy, toxicity profiles. We examine how circRNA-mediated regulatory networks influence chemotherapy alter targeted therapy responses, impact immunotherapy outcomes. Additionally, we discuss emerging experimental tools bioinformatics techniques for studying circRNAs, including multi-omics integration, machine learning-driven biomarker discovery, high-throughput sequencing technologies. Beyond diagnostic potential, are being actively explored agents delivery vehicles. Recent advancements circRNA-based vaccines, engineered CAR-T cells, synthetic circRNA therapeutics highlight transformative potential oncology. Furthermore, address challenges standardization, reproducibility, clinical translation, emphasizing need rigorous validation frameworks facilitate integration into practice. By incorporating profiling pharmacogenomic strategies, this underscores paradigm shift toward highly personalized therapies. hold immense overcome enhance treatment optimize patient outcomes, marking significant advancement

Language: Английский

Citations

0